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Abstract
Purpose To evaluate the prognostic value of IGF-1R expression on circulating tumor cells (CTCs) in a prospective rand-
omized clinical trial comparing chemotherapy plus metformin with chemotherapy alone in metastatic breast cancer (MBC) 
patients.
Methods CTCs were collected at baseline and at the end of chemotherapy. An automated sample preparation and analysis 
system (CellSearch) were customized for detecting IGF-1R expression. The prognostic role of CTC count and IGF-1R was 
assessed for PFS and OS by univariate and multivariate analyses.
Results Seventy-two out of 126 randomized patients were evaluated: 57% had ≥ 1 IGF-1R positive CTC and 37.5% ≥ 4 IGF-
1R negative cells; 42% had CTC count ≥ 5/7.5 ml. At univariate analysis, the number of IGF-1R negative CTCs was strongly 
associated with risk of progression and death: HR 1.93 (P = 0.013) and 3.65 (P = 0.001), respectively; no association was 
detected between number of IGF-1R positive CTCs and PFS or OS (P = 0.322 and P = 0.840). The prognostic role of CTC 
count was confirmed: HR 1.69, P = 0.042 for PFS and HR 2.80 for OS, P = 0.002. By multivariate analysis, the prognostic 
role of the number of IGF-1R negative CTCs was maintained, while no residual prognostic role of CTC count or number of 
IGF-1R positive cells was found.
Conclusion Loss of IGF-1R in CTCs is associated with a significantly worse outcome in MBC patients. This finding sup-
ports further evaluation for the role of IGF-1R on CTCs to improve patient stratification and to implement new targeted 
strategies. Clinical trial registration: Clinicaltrials.gov (NCT01885013); European Clinical Trials Database (EudraCT 
No.2009-014,662-26).
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IGF-1R  Insulin-like growth factor-1 receptor
CTCs  Circulating tumor cells
MBC  Metastatic breast cancer
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IRS-2  Insulin receptor substrate-2
Introduction
In the past 15 years, a substantial body of evidence has 
developed regarding the role of insulin and the insulin-
like growth factor (IGF) family in breast cancer (BC) [1, 
2]. Along with the metabolic effects of insulin on glucose 
balance, insulin has also been shown to induce cancer cell 
proliferation: this effect might explain the adverse prognos-
tic effect of hyperinsulinemia in BC patients, observed in 
epidemiological studies [3, 4].
The pathways downstream of the insulin/IGF system are 
well defined: IGF-1 and insulin activate the tyrosine kinase 
receptor pathway, i.e., the insulin, IGF-1 and hybrid IGF-1/
insulin receptors, all of which are overexpressed in BC cells. 
Activation of these receptors results in upregulation of the 
 * Alessandra Gennari 
 alessandra.gennari@uniupo.it
Extended author information available on the last page of the article
62 Breast Cancer Research and Treatment (2020) 181:61–68
1 3
Insulin Receptor Substrate-2 (IRS2), leading to downstream 
activation of the MAPKinase and PI3K-Akt pathways. More-
over, insulin itself may also modulate circulating levels of 
IGFs and their binding proteins [5]. These data suggest that 
the insulin pathway plays a major role in BC prognosis and 
may represent a therapeutic target, especially in those patients 
exposed to high insulin plasmatic level. It has been observed 
that in women with early BC, hyperinsulinemia is associated 
with the presence of insulin resistance, hence, the development 
of therapies targeting hyperinsulinemia is currently one of the 
most intriguing fields of research in BC as well as in other 
types of cancer [6].
Recent interest has focused on metformin, an antidiabetic 
drug widely prescribed for the treatment of hyperglycemia and 
hyperinsulinemia. The main systemic effect of metformin in 
reducing the circulating level of IGF-1/insulin has been asso-
ciated with anticancer action [7]. However, so far, metabolic 
targeting in patients with solid tumors, did not translate into a 
measurable clinical benefit [8, 9]. Possible reasons for failure 
include the complexity of the IGF-1R/insulin receptor system 
and the presence of parallel pathways of growth and survival, 
as well as the lack of appropriate patient selection markers 
[10].
Effective tools in the identification of patients likely to 
benefit from targeted therapies are needed to optimize patient 
selection and treatment effectiveness. Circulating tumor cell 
(CTC) isolation and characterization has been proposed as a 
tool for patient selection in MBC, being associated with prog-
nosis and response to treatment [11, 12]. CTCs can be eas-
ily evaluated in peripheral blood by “liquid biopsy”, with a 
minimally invasive procedure. The molecular features of CTCs 
can also be profiled by fluorescence in situ hybridization or 
immunofluorescence, supporting their use as a noninvasive 
approach for patient selection. The analysis of IGF-1R expres-
sion on CTCs, previously described by de Bono, is particularly 
appealing due to the role of the insulin/IGF pathway in tumor 
metastasis, cancer cell proliferation, invasion, and angiogen-
esis [13, 14].
To evaluate the potential impact of metabolic targeting in 
advanced BC, we have conducted a phase II randomized clini-
cal trial, comparing the association of metformin plus chemo-
therapy (CT) with CT alone, as first line treatment in HER2 
negative, non-diabetic, MBC patients (MYME trial) [15]. We 
present here the final results of the TransMyme study, nested 
in the MYME clinical trial and aimed at evaluating the prog-
nostic role of IGF-1R expression on CTCs.
Patients and methods
Eligibility criteria
The TransMyme study was nested in MYME trial, a phase 
II comparative trial, of AC (non-pegylated liposomal dox-
orubicin 60 mg/m2 + cyclofosfamide 600 mg/m2, × 6/8 
cycles Q21) versus AC plus Metformin (2000 mg pos 
daily until disease progression), that enrolled 126 HER2-
negative, non-diabetic, MBC patients, at first evidence 
of disease relapse, between April 2010 and May 2015. 
The study was approved by the Ethics Committees of all 
the participating centers. Written informed consent was 
obtained from all patients before study entry. Eligibility 
criteria included: stage IV histologically confirmed MBC; 
measurable and/or non-measurable disease, availability of 
HOMA index calculated according to Matthews’ formula 
[16], prior endocrine therapy was allowed in the adjuvant 
and/or metastatic setting; prior chemotherapy was allowed 
in the adjuvant setting, including anthracyclines; patients 
with known diabetes (type 1 or 2) were excluded. Stag-
ing procedures for disease evaluation were performed at 
baseline and every two months afterwards.
A HOMA index ≥ 2.5 was chosen as the  cut-off value 
for insulin resistance based on the results from an Ital-
ian-based population study [17]. Progression-free sur-
vival (PFS) was the primary outcome measure and it was 
calculated from the date of randomization to the date of 
disease progression, death from any cause, or loss to fol-
low-up, whichever came first. One hundred twenty-two 
patients were evaluable for PFS. At a median follow-up of 
39.6 months (interquartile range [IQR] 24.6–50.7 months), 
112 disease progressions and 71 deaths have been regis-
tered. Median PFS was 9.4 months (95% CI 7.8–10.4) for 
patients treated with AC plus metformin and 9.9 (95% CI 
7.4–11.5) for patients treated with AC (P = 0.651). 
In patients with HOMA index < 2.5, median PFS was 
10.4  months (95% CI 9.6–11.7) versus 8.5 (95% CI 
5.8–9.7) in those with HOMA index ≥ 2.5 (P = 0.034). The 
effect of metformin was similar in patients with HOMA 
index < 2.5 and ≥ 2.5, in terms of PFS and OS.
The study was conducted in accordance with the Decla-
ration of Helsinki, Good Clinical Practice norms and local 
and national regulatory requirements.
CTC assessment
For CTC evaluation, blood samples were collected at base-
line, at the end of CT administration (cycle 6 or 8) and at 
evidence of disease progression. All blood samples were 
collected into CellSave® Preservative Tubes and centrally 
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processed within 96 h after blood draw, at the CTC labora-
tory of IOV-IRCCS. CTC results were blinded to the refer-
ence physician. The CellSearch System (Menarini Silicon 
Biosystems, LLC) was used to count CTCs in peripheral 
blood, according to the manufacturer’s instructions and 
users’ guidelines [18, 19]. An event was classified as a 
CTC when its morphological features were consistent with 
that of a cell and it exhibited the phenotype EpCAM + , 
Cytokeratin 8, 18, 19 + (CK +), DAPI + and CD45.
Phenotypic profiling of CTC 
To clarify the mechanism of putative modulation of insu-
lin/IGF pathway throughout the treatment with metformin, 
IGF-1R positive CTCs were detected integrating CTC assay 
with specific monoclonal antibody, as previously reported 
for other customized tests [13, 19], by integrating the CXC 
kit (Menarini) with a specific mAb for detecting IGF-1R 
expression (Clone 33,255, #MAB391, R&D Systems, Min-
neapolis, MN, USA); the anti-IGF-1R was conjugated with 
Phycoerythrin (PE), (AcZon, Nano Biotech, Bologna, BO, 
Italy).
Results were expressed as the total number of CTCs, IGF-
1R positive, and IGf-1R-negative CTCs per 7.5 ml of blood 
at each time-point.
IGF‑1R CTC assay in house re‑editing
An online staining procedure based on the CellSearch plat-
form was used to obtain with a single test tube both the 
CTC count and the IGF-1R expression’ level. Advantages 
of this approach are that anti-IGF-1R is added and pro-
cessed simultaneously with the CK-FITC and CD45-APC 
antibodies, thus minimizing cell loss or disruption during 
permeabilization and staining steps, performed by the auto-
mated platform. To this purpose, the test firstly exploited 
by de Bono et al. [13] was re-edited in house. At first, the 
IGF-1R PE was used in conjunction with the CXC kit, to 
specifically quantify IGF-1R expression on the MCF7 cell 
line (a human BC cell line) that express this antigen in 80% 
of the population at low fluorescence intensity, but with a 
good resolution of signal to background (data not shown).
MCF7 cells were then spiked into whole blood sample 
of healthy donors, at numbers like those observed in vivo 
in cancer patients (200–1000 cells/7.5 ml peripheral blood) 
to be finally processed by CellSearch System. The IGF-
1R-integrated CTC assay was then fully developed in blood 
samples obtained from healthy donors and cancer patients.
The integrated CTC assay clearly showed to discriminate 
IGF-1R-positive and IGF-1R-negative cells (Fig. 1), accord-
ing to morphological features included in CTC definition by 
users’ guidelines (clear visible nucleus of at least 4-micron 
diameter, cytoplasmic/nuclear areas overlapping more than 
50%, uniformly CK staining of cytoplasm) and on the basis 
of staining profile (sufficient resolution of signal to back-
ground in the fourth “customized” filter).
Statistical analysis
Categorical variables were expressed as counts (%) for cat-
egorical variables and median and interquartile range (IQR) 
for continuous variables. Time-to-event data (PFS, OS) were 
described using the Kaplan–Meier curves and compared 
with the log-rank test. Ninety-five percent confidence inter-
vals (95% CI) were calculated by non-parametric methods. 
Estimated HRs with 95% CI were calculated using univariate 
Fig. 1  IGF-1R CTC assays
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and multivariate Cox proportional hazard models. PFS and 
OS were measured as the time between date of study entry 
and the disease progression or death. Patients alive and free 
from disease progression at the time of analysis were cen-
sored, using the time between the baseline CTC count and 
the most recent follow-up evaluation. A receiver operating 
characteristics (ROC) analysis was conducted to identify the 
best IGF-1R cut-off able to divide patients in two classes 
according to PFS. Univariate and multivariate analyses by 
CTC number and number of IGF-1R negative CTC were 
performed. The differential effect of metformin on PFS and 
OS was evaluated by testing the interaction between treat-
ment arm and CTC number and IGF-1R expression. P < 0.05 
was considered statistically significant. Statistical analyses 
were performed using STATA/MP 15.0 for Windows (Stata-
CorpLP, College Station, TX, USA). No correction for mul-
tiple testing was applied.
Results
Seventy-nine out of 126 patients enrolled into the MYME 
trial (62.7%) were prospectively included in the TransMyme 
study on CTCs; of these, 72 are included in the present anal-
ysis. Figure 2 illustrates the patient selection process in the 
TransMyme study. At baseline, 30 out of 72 patients (42.0%) 
had > 5 CTCs/7.5 ml of blood and 41 (57.0%) had at least 1 
IGF-1R-positive CTC; 27 patients (37.5%) had ≥ 4 IGF-1R 
negative cells. Patient characteristics are reported in Table 1.
Median PFS in patients with CTC count < 5/7.5 ml was 
10.8 months (95% CI 8.1–11.7) versus 8.3 months (95% CI 
6.3–9.7) in patients with CTC count ≥ 5/7.5 ml (HR 1.69 
(95% CI 1.02–2.79), P = 0.042, Fig. 3a). Similarly, a sig-
nificantly longer OS was observed: 37.0 months (95% CI 
26.8-NE) versus 17.9 (95% CI 13.7–22.2); HR 2.80 (95% 
CI 1.47–5.30), P = 0.002, Fig. 3b.
When CTCs were characterized according to IGF-1R 
expression level, i.e., IGF-1R positive (n = 41) and IGF-1R 
negative (n = 31), a striking difference was observed in their 
prognostic effect: median PFS was 10.1 months (95% CI 
7.4–11.5) in patients with < 1 IGF-1R positive CTCs and 
9.6 months (95% CI 7.3–11.5) in patients with ≥ 1 IGF-1R 
positive CTC (HR = 0.78; 95% CI 0.48–1.27, P = 0.322). 
Conversely, median PFS was 7.9 months (95% CI 3.4–9.7) 
in patients with ≥ 4 IGF-1R-negative CTCs versus 10.7 (95% 
CI 9.2–11.7) in patients with < 4 IGF-1R negative CTCs 
(HR 1.93; 95% CI 1.15–3.23, P = 0.013) (Fig. 3c).
Similarly, no association between the number of IGF-
1R positive CTCs and OS was found: median OS was 
22.2 months (95% CI 16.6-NE) in patients with < 1 IGF-
1R positive CTCs and 30.8 months (95% CI 17.9–37.2) in 
patients with ≥ 1 IGF-1R positive CTCs (HR 0.94; 95% CI 
0.49–1.78, P = 0.840). Median OS was 37 months (95% CI 
28.6-NE) in patients with < 4 IGF-1R negative CTCs versus 
Fig. 2  TransMyme study flow 
diagram
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16.8 (95% CI 12.5–19.0, P =  < 0.001) in patients with ≥ 4 
IGF-1R-negative CTCs (HR = 3.65; 95% CI 1.88–7.09, 
P < 0.001) (Fig. 3d).
At multivariate analysis, the prognostic role of the num-
ber of IGF-1R negative CTCs was confirmed in terms of 
OS, while no residual prognostic effect of the total number 
of CTCs was detected; results are shown in Table 2. Simi-
lar data were obtained, when HOMA index and BMI were 
added to the model.
In an exploratory analysis, the role of IGF-1R expression 
and CTC count was evaluated by treatment arm: no evidence 
of interaction between IGF-1R expression or CTC count and 
metformin was detected, either in terms of PFS or OS.
Treatment induced modification in IGF-1R expression 
and CTC count was investigated in 55 out of 72 patients 
(76.4%) with paired blood samples collected at baseline and 
after the end of treatment; of these, 31 (56.4%) received 
chemotherapy alone and 24 (43.6%) the combination of 
chemotherapy and metformin. Overall, in terms of PFS no 
effect due to modification in the number of IGF-1R nega-
tive CTC or CTC count was observed (P = 0.10 and 0.13, 
respectively). In terms of OS, a striking difference was 
detected: median OS was 41.4 months (95% CI 30.8 – NE) 
in 36 patients with no change in IGF-1R negative CTCs 
(< 4 IGF-1R), 20.1 months (95% CI 15.2-NE) in 14 patients 
with ≥ 4 IGF-1R negative CTC at baseline and < 4 after 
treatment, and 12.4 months (95% CI 10.1-NE) in 5 patients 
with ≥ 4 IGF-1R negative CTCs and no change with treat-
ment (P =  < 0.0001).
Similarly, median OS was 37 months (95% CI 30.8-NE) 
in 31 patients with no change in CTC count (< 5/7.5 ml), 
22.2 months (95%CI 15.2-NE) in 15 patients with a base-
line CTC count ≥ 5/7.5 ml and < 5/7.5 ml after treatment and 
12.4 months (95% CI 10.1-NE) in 9 patients with no change 
in CTC count (≥ 5/7.5 ml) or an increase to ≥ 5/7.5 ml CTCs 
(P < 0.0001).
By multivariate analysis, no effect of metformin on modi-
fications in IGF-1R expression or CTC count was observed 
(P = 0.63).
Discussion
The TransMyme study was nested in the MYME trial com-
paring first line CT with first line CT plus metformin in 
MBC. Overall, results excluded any beneficial effect of met-
formin in combination with CT either in terms of PFS or 
OS. The primary objective of the TransMyme study was 
to evaluate the potential prognostic and predictive role of 
IGF-1R expression on CTCs. IGFs are endocrine mediators 
of growth hormones and also act in paracrine and autocrine 
fashion to regulate cell growth, differentiation, apoptosis, 
and transformation in many tissues including the breast 
[20]. Activation of these receptors by IGFs or insulin has 
been shown to induce the downstream activation of the 
MAPKinase and PI3K-Akt pathways, thus enhancing can-
cer cell proliferation and survival, as well as resistance to 
CT in BC [21]. In this regard, our results indicate a strong 
adverse prognostic effect of the lack of IGF-1R expression 
on CTCs, with an almost doubled risk of progression and 
death for those patients with ≥ 4 IGF-1R negative CTCs. At 
the same time, the adverse prognostic effect of CTC count 
was confirmed at univariate analysis, with a significantly 
worse PFS and OS in patients with a baseline value of ≥ 5 
CTCs/7.5 ml of blood, in line with what previously observed 
in larger cohorts [22]. However, when a multivariate model, 
including CTC characterization and CTC count was applied, 
the adverse prognostic value of number of IGF-1R nega-
tive CTCs was confirmed, whereas the prognostic value 
Table 1  Patients’ characteristics
TransMyme study 
population (n = 72)
MYME study 
population 
(n = 122)
Median age, years (IQR 
range)
59 (50–67) 60 (51–66)
Post-menopausal 57 (79.2%) 100 (82.0%)
ER-positive 61 (84.7%) 106 (86.9%)
ECOG performance status
 0 57 (79.2%) 94 (77.1%)
 1 14 (19.4%) 26 (21.3%)
 2 1 (1.4%) 2 (1.6%)
Prior adjuvant chemotherapy 43 (59.7%) 73 (59.8%)
Prior adjuvant endocrine 
therapy
42 (58.3) 75 (61.5%)
Prior endocrine therapy for 
MBC
26 (36.1) 44 (36.1%)
Dominant metastatic site
 Bone only 12 (16.7%) 19 (15.6%)
 Viscera 49 (68.1%) 78 (63.9%)
 Soft tissue 11 (15.2%) 25 (20.5%)
No. of metastatic sites
 1 24 (33.3%) 39 (31.9%)
 2 20 (27.8%) 40 (32.8%)
  > 2 28 (38.9%) 43 (35.3%)
Body mass index (BMI)
  < 25 30 (41.7%) 51 (41.8%)
  ≥ 25 and < 30 29 (40.3%) 50 (41.0%)
  > 30 13 (18.0%) 21 (17.2%)
HOMA index
  < 2.5 41 (56.9%) 65 (53.3%)
  ≥ 2.5 31 (43.1%) 57 (46.7%)
Metformin treatment 38 (52.8%) 57 (46.7%)
Median insulin value (IQR 
range)
8.70 (7–14.2) 9.75 (7.0–14.8)
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of CTC count was not maintained. The possible predictive 
role of IGF-1R expression on CTCs could not be demon-
strated, since any interaction between IGF-1R expression 
and metformin was detected. Finally, an exploratory analysis 
on treatment induced modification in IGF-1R CTC expres-
sion suggested that the acquisition of a “bad phenotype” 
(i.e., ≥ 4 IGF-1R negative CTCs) resulted in a significantly 
worse overall survival. However, these data on paired blood 
samples, were achieved in a smaller number of patients, and 
should be interpreted with caution.
The phenotypic characterization of CTCs has been pro-
posed as a non invasive prognostic and predictive tool to 
address treatment selection. In particular, IGF-1R expres-
sion on CTCs has been previously demonstrated in dif-
ferent tumor types. In 2007, Bono et al. [13] showed that 
IGF-1R is frequently expressed in CTCs of patients with 
metastatic tumors and, a few years later, Pizon et al [23]. 
reported that 84% of BC patients harbored IGF-1R posi-
tive CTCs. More recently, the expression of IGF-1R was 
evaluated in 85 CTC-positive patients with early (n = 28) 
Fig. 3  Kaplan–Meier curves of PFS and OS: Kaplan–Meier curves 
for PFS (a) and OS (b) of MBC patients with CTC count < 5/7.5 ml 
versus ≥ 5/7.5  ml and Kaplan–Meier curves for PFS (c) and OS (d) 
of MBC patients with ≥ 4 IGF-1R negative CTCs versus < 4 IGF-1R 
negative CTCs
Table 2  Prognostic role of 
number of IGF-1R negative 
CTCs and CTC count: 
univariate and multivariate 
analyses
Univariate analysis Multivariate analysis
PFS HR (95% CI) OS HR (95% CI) PFS HR (95% CI) OS HR (95% CI)
IGF-1R neg < 4 1 1 1 1
IGF-1R neg ≥ 4 1.93 3.65 1.79 2.83
(1.15–3.23) (1.88–7.09) (0.78–4.16) (1.09–7.39)
CTC < 5/7.5 mL 1 1 1 1
CTC ≥ 5/7.5 mL 1.69 2.80 1.09 1.41
(1.02–2.79) (1.47–5.30) (0.48–2.48) (0.55–3.59)
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and advanced (n = 57) BC [24]. In this study, IGF-1R 
expression was detected in 79% of CTC-positive MBC; 
conversely, 21% of the patients had exclusively IGF-1R 
negative CTCs. A reduction in the frequency of IGF-1R 
positive CTCs was observed with transition from early 
to the metastatic stage, suggesting a potential association 
between IGF-1R expression and BC aggressiveness, as 
hypothesized by pre-clinical data showing a correlation 
between IGF-1R expression level and metastatic potential 
[25, 26]. In this study, we prospectively evaluated for the 
first time, the prognostic effect of IGF-1R expression on 
CTCs in MBC patients randomized into a clinical trial 
of first line CT. In conclusion, the TransMyme study is 
the largest prospective study to date that has evaluated 
the prognostic and predictive role of the expression IGF-
1R on CTCs, in MBC patients treated with first line CT. 
Our results indicate that the lack of IGF-1R expression on 
CTCs is significantly correlated with an adverse prognosis 
in this patient population. This IGF-1R dependent effect is 
maintained at multivariate analysis, whereas the effect of 
CTC count is lost. These data should also be considered 
in the multivariate landscape of the “metabolic approach” 
to breast cancer. In the past 10 years, several studies have 
evaluated the impact of targeting the insulin-IGF axis as a 
treatment strategy in early and advanced BC. In our expe-
rience, we performed two randomized clinical trials in BC: 
in the MYME study [15], no evidence of an improvement 
in terms of PFS was shown with the addition of metformin 
to conventional chemotherapy in MBC. In the second win-
dow of opportunity study [9], we evaluated the effect of 
metformin single agent at standard antidiabetic dosages, 
on tumor cell proliferation (ki67) as compared to matching 
placebo, in the preoperative setting of early BC: again no 
significant effect was detected.
Conversely, a number of clinical studies evaluating anti-
IGF drugs (either monoclonal antibodies or TKI inhibi-
tors) reported inconsistent results or were complicated by 
excessive metabolic toxicity (hyperglycemia). Other trials 
with metformin and anti-IGF agents are ongoing. In these 
perspective, our data, showing a clear prognostic role of 
IGF-1R expression on CTCs, together with the moderate 
impact of a non-invasive liquid biopsy approach, could 
improve patient stratification to better address a strategy 
of “metabolic targeting” in BC.
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